Sign In
Buy ILMN
$205.10
+0.0100 (+0.0049%)
At Close: Jul 31, 2026
REGN or ILMN: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 23'rd Jan 2026
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Regeneron (REGN) and Illumina (ILMN). But which of these two stocks presents investors w
11,407 Shares in Illumina, Inc. $ILMN Acquired by Inscription Capital LLC
04:45am, Wednesday, 21'st Jan 2026
Inscription Capital LLC bought a new position in shares of Illumina, Inc. (NASDAQ: ILMN) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchan
Illumina Gets Medicare Boost for Cancer Test, Shares Climb
01:19pm, Tuesday, 20'th Jan 2026
Illumina Inc. (NASDAQ: ILMN) shares are up on Tuesday following news that the company has secured reimbursement for its FDA-approved TruSight Oncology Comprehensive test.
Illumina secures CMS reimbursement for TruSight™ Oncology Comprehensive, expanding access to precision oncology
09:15am, Tuesday, 20'th Jan 2026
The FDA-approved comprehensive genomic profiling test will be reimbursed at a rate of $2,989.55 per test, helping to advance adoption in the US healthcare system SAN DIEGO, Jan. 20, 2026 /PRNewswire/
GRAIL Inc. - Illumina's Divested Holy Grail
08:34am, Tuesday, 20'th Jan 2026
GRAIL (GRAL) offers MCED screening tests that offer employers economic value and employee health clarity. Divestiture of GRAIL by Illumina offers investors $8B valuation foundation. TAM valuation impl
Cathie Wood's Ark Invest unveiled its "big ideas" for 2025 in a cryptic list, challenging users to interpret a series of custom images called "ARKmoji" to understand their picks for the year.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
09:57am, Thursday, 15'th Jan 2026
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
02:25pm, Tuesday, 13'th Jan 2026
Illumina, Inc. (ILMN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Illumina unveils dataset to speed up AI-powered drug discovery
09:18am, Tuesday, 13'th Jan 2026
Gene sequencing company Illumina on Tuesday introduced a dataset that maps genetic changes to help accelerate drug discovery through artificial intelligence.
Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
09:15am, Tuesday, 13'th Jan 2026
The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today introduced the wor
Illumina Announces Preliminary Unaudited Financial Results for Fourth Quarter and Fiscal Year 2025
09:00am, Tuesday, 13'th Jan 2026
SAN DIEGO, Jan. 13, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025
Illumina to Announce Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 5, 2026
04:07pm, Monday, 12'th Jan 2026
SAN DIEGO, Jan. 12, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the fourth quarter and full year 2025 following the close of market on Thursday, Fe
Illumina's New Connected Multiomics Platform Set to Boost Its Stock
09:11am, Monday, 12'th Jan 2026
ILMN's Connected Multiomics, launched after early user input, advances precision health research and may boost the stock.
Cerity Partners LLC Increases Stock Position in Illumina, Inc. $ILMN
03:24am, Sunday, 11'th Jan 2026
Cerity Partners LLC boosted its position in Illumina, Inc. (NASDAQ: ILMN) by 23.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchang
Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?
01:10pm, Friday, 09'th Jan 2026
Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
